Source:http://linkedlifedata.com/resource/pubmed/id/19253367
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
2009-4-1
|
pubmed:abstractText |
Recent studies have indicated that somatic mutations in the epidermal growth factor receptor (EGFR) gene have been identified in a subset of patients with nonsmall-cell lung cancer (NSCLC) and are associated with sensitivity to the EGFR-tyrosine-kinase inhibitors. These mutations have been reported to be almost exclusively found in a pulmonary adenocarcinoma subgroup of NSCLC, with a low frequency in other solid tumors. We describe a patient with advanced-stage papillary thyroid carcinoma (PTC) whose disease had been diagnosed as pulmonary adenocarcinoma at first, and who had a marked response to the EGFR-tyrosine-kinase inhibitor, gefitinib. An in-frame deletion in exon 19 that eliminated 4 amino acids at positions 746 through 750, which is one of the common drug-sensitive mutations in pulmonary adenocarcinoma, and a serine-to-proline substitution at codon 752, were found in a tumor specimen of the patient. We subsequently searched for mutations in the EGFR tyrosine kinase domain in primary tumors from 23 patients with PTC, and drug-sensitive mutations commonly observed in pulmonary adenocarcinoma were found in 7 of these patients. Our observation of a high frequency of the EGFR-activating mutations in PTC suggests that the EGFR mutation may be an important event in the development of PTC. EGFR gene amplification, also considered to be a predictor of response to EGFR-tyrosine-kinase inhibitors, was evaluated by fluorescence in situ hybridization (FISH); however, only 1 FISH-positive tumor was detected. Our data suggest that EGFR-tyrosine-kinase inhibitors may deserve consideration in the treatment of a subset of patients with PTC, just as with pulmonary adenocarcinoma.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
1097-0215
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:day |
1
|
pubmed:volume |
124
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2744-9
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:19253367-Adult,
pubmed-meshheading:19253367-Aged,
pubmed-meshheading:19253367-Carcinoma, Papillary,
pubmed-meshheading:19253367-Female,
pubmed-meshheading:19253367-Humans,
pubmed-meshheading:19253367-Male,
pubmed-meshheading:19253367-Mutation,
pubmed-meshheading:19253367-Proto-Oncogene Proteins B-raf,
pubmed-meshheading:19253367-Receptor, Epidermal Growth Factor,
pubmed-meshheading:19253367-Thyroid Neoplasms
|
pubmed:year |
2009
|
pubmed:articleTitle |
Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma.
|
pubmed:affiliation |
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
|
pubmed:publicationType |
Journal Article,
Case Reports
|